Your browser doesn't support javascript.
loading
Beyond Bronchiolitis Obliterans: In-Depth Histopathologic Characterization of Bronchiolitis Obliterans Syndrome after Lung Transplantation.
Vanstapel, Arno; Verleden, Stijn E; Verbeken, Eric K; Braubach, Peter; Goos, Tinne; De Sadeleer, Laurens; Kaes, Janne; Vanaudenaerde, Bart M; Jonigk, Danny; Ackermann, Maximilian; Ceulemans, Laurens J; Van Raemdonck, Dirk E; Neyrinck, Arne P; Vos, Robin; Verleden, Geert M; Weynand, Birgit.
Afiliación
  • Vanstapel A; Department of Chronic Diseases and Metabolism, BREATHE, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
  • Verleden SE; Department of Pathology, University Hospitals Leuven, 3000 Leuven, Belgium.
  • Verbeken EK; Department of Chronic Diseases and Metabolism, BREATHE, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
  • Braubach P; Antwerp Surgical Training, Anatomy and Research Centre (ASTARC), University of Antwerp (UA), 2610 Wilrijk, Belgium.
  • Goos T; Department of Thoracic & Vascular Surgery, University Hospital Antwerp (UZA), 2650 Edegem, Belgium.
  • De Sadeleer L; Department of Pneumology, University Hospital Antwerp (UZA), 2650 Edegem, Belgium.
  • Kaes J; Department of Pathology, University Hospitals Leuven, 3000 Leuven, Belgium.
  • Vanaudenaerde BM; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Hannover Medical School, 30625 Hannover, Germany.
  • Jonigk D; Department of Chronic Diseases and Metabolism, BREATHE, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
  • Ackermann M; Department of Respiratory Diseases, University Hospitals Leuven, 3000 Leuven, Belgium.
  • Ceulemans LJ; Department of Chronic Diseases and Metabolism, BREATHE, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
  • Van Raemdonck DE; Department of Respiratory Diseases, University Hospitals Leuven, 3000 Leuven, Belgium.
  • Neyrinck AP; Department of Chronic Diseases and Metabolism, BREATHE, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
  • Vos R; Department of Chronic Diseases and Metabolism, BREATHE, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
  • Verleden GM; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Hannover Medical School, 30625 Hannover, Germany.
  • Weynand B; Institute of Pathology and Department of Molecular Pathology, Helios University Clinic Wuppertal, University of Witten-Herdecke, 58455 Witten, Germany.
  • On Behalf Of The Leuven Lung Transplant Group; Institute of Functional and Clinical Anatomy, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
J Clin Med ; 11(1)2021 Dec 25.
Article en En | MEDLINE | ID: mdl-35011851
ABSTRACT
Bronchiolitis obliterans syndrome (BOS) is considered an airway-centered disease, with bronchiolitis obliterans (BO) as pathologic hallmark. However, the histologic spectrum of pure clinical BOS remains poorly characterized. We provide the first in-depth histopathologic description of well-characterized BOS patients and patients without chronic lung allograft dysfunction (CLAD), defined according to the recent consensus guidelines. Explant lung tissue from 52 clinically-defined BOS and 26 non-CLAD patients (collected 1993-2018) was analyzed for histologic parameters, including but not limited to airway lesions, vasculopathy and fibrosis. In BOS, BO lesions were evident in 38 (73%) patients and varied from concentric sub-epithelial fibrotic BO to inflammatory BO, while 10/14 patients without BO displayed 'vanishing airways', defined by a discordance between arteries and airways. Chronic vascular abnormalities were detected in 22 (42%) patients. Ashcroft fibrosis scores revealed a median of 43% (IQR 23-69) of normal lung parenchyma per patient; 26% (IQR 18-37) of minimal alveolar fibrous thickening; and 11% (IQR 4-18) of moderate alveolar thickening without architectural damage. Patchy areas of definite fibrotic damage to the lung structure (i.e., Ashcroft score ≥5) were present in 28 (54%) patients. Fibrosis was classified as bronchocentric (n = 21/28, 75%), paraseptal (n = 17/28, 61%) and subpleural (n = 15/28, 54%). In non-CLAD patients, BO lesions were absent, chronic vascular abnormalities present in 1 (4%) patient and mean Ashcroft scores were significantly lower compared to BOS (p = 0.0038) with 78% (IQR 64-88) normally preserved lung parenchyma. BOS explant lungs revealed evidence of various histopathologic findings, including vasculopathy and fibrotic changes, which may contribute to the pathophysiology of BOS.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: J Clin Med Año: 2021 Tipo del documento: Article País de afiliación: Bélgica

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: J Clin Med Año: 2021 Tipo del documento: Article País de afiliación: Bélgica